An overview of early investigational therapies for chemoresistant ovarian cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An overview of early investigational therapies for chemoresistant ovarian cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 24, Issue 9, Pages 1163-1183
Publisher
Informa Healthcare
Online
2016-02-13
DOI
10.1517/13543784.2015.1072168
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
- (2017) H. W. Hirte et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
- (2017) S. Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).
- (2017) R. J. Buckanovich et al. JOURNAL OF CLINICAL ONCOLOGY
- Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial.
- (2017) Gael Deplanque et al. JOURNAL OF CLINICAL ONCOLOGY
- Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy
- (2015) Chiara Della Pepa et al. CANCER TREATMENT REVIEWS
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
- (2015) S. Kummar et al. CLINICAL CANCER RESEARCH
- A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
- (2015) E. G. Chiorean et al. CLINICAL CANCER RESEARCH
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Updates and emerging therapies for rare epithelial ovarian cancers: One size no longer fits all
- (2015) Reinou S. Groen et al. GYNECOLOGIC ONCOLOGY
- The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
- (2015) Seiji Mabuchi et al. GYNECOLOGIC ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- (2015) Sandro Pignata et al. LANCET ONCOLOGY
- A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†
- (2014) I. A. McNeish et al. ANNALS OF ONCOLOGY
- A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer
- (2014) Komal Jhaveri et al. Clinical Breast Cancer
- First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
- (2014) M. E. Elez et al. CLINICAL CANCER RESEARCH
- A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
- (2014) Ignace Vergote et al. GYNECOLOGIC ONCOLOGY
- A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
- (2014) Lipika Goyal et al. INVESTIGATIONAL NEW DRUGS
- Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
- (2014) Martin R. Stockler et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
- (2014) Dineo Khabele Frontiers in Oncology
- New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
- (2013) D S P Tan et al. BRITISH JOURNAL OF CANCER
- Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
- (2013) T. Liu et al. CLINICAL CANCER RESEARCH
- Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer
- (2013) H. Liu et al. CLINICAL CANCER RESEARCH
- Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
- (2013) J. E. Ang et al. CLINICAL CANCER RESEARCH
- Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?
- (2013) Ilaria Marech et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer
- (2013) Samuel J Klempner et al. EXPERT OPINION ON PHARMACOTHERAPY
- Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study
- (2013) Gabriella Ferrandina et al. GYNECOLOGIC ONCOLOGY
- Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy
- (2013) Timothy J. Judson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma
- (2013) Hyo Jeong Kang et al. PLoS One
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
- (2012) K. H. Baumann et al. ANNALS OF ONCOLOGY
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
- (2012) E Dean et al. BRITISH JOURNAL OF CANCER
- Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
- (2012) A. Vidal et al. CLINICAL CANCER RESEARCH
- A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
- (2012) S. B. Kaye et al. CLINICAL CANCER RESEARCH
- Olaparib, PARP1 inhibitor in ovarian cancer
- (2012) Claudia Marchetti et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer
- (2012) Ursula A. Matulonis et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
- (2012) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
- (2012) Susana M. Campos et al. GYNECOLOGIC ONCOLOGY
- Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer
- (2012) Don S. Dizon et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
- (2012) Nicoletta Colombo et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- (2012) John Farley et al. LANCET ONCOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
- (2011) W. Hu et al. CANCER RESEARCH
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors*,†
- (2011) Noboru Yamamoto et al. CANCER SCIENCE
- IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
- (2011) M. S. Anglesio et al. CLINICAL CANCER RESEARCH
- Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms
- (2011) Filippo Bellati et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
- (2011) Joyce Varughese et al. GYNECOLOGIC ONCOLOGY
- Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
- (2011) Lubomir Bodnar et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
- (2011) R. Ramasubbaiah et al. GYNECOLOGIC ONCOLOGY
- A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
- (2011) Nicoletta Colombo et al. GYNECOLOGIC ONCOLOGY
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
- (2011) Robert L Coleman et al. LANCET ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
- (2011) Walter H Gotlieb et al. LANCET ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
- (2010) A. Poveda et al. ANNALS OF ONCOLOGY
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
- (2010) J. J. Biagi et al. ANNALS OF ONCOLOGY
- Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
- (2010) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
- (2010) Helen J. Mackay et al. EUROPEAN JOURNAL OF CANCER
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer
- (2010) Stephen A. Welch et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
- (2010) Ignace Vergote et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary
- (2010) Seiji Mabuchi et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ovarian Low-grade and High-grade Serous Carcinoma
- (2009) Russell Vang et al. ADVANCES IN ANATOMIC PATHOLOGY
- Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
- (2009) Beverly L. Falcón et al. AMERICAN JOURNAL OF PATHOLOGY
- Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
- (2009) R Sharma et al. BRITISH JOURNAL OF CANCER
- A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer
- (2009) Ignace Vergote et al. EUROPEAN JOURNAL OF CANCER
- First-line treatment of advanced ovarian cancer: current research and perspectives
- (2009) Claudia Marchetti et al. Expert Review of Anticancer Therapy
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
- (2008) N Nakayama et al. BRITISH JOURNAL OF CANCER
- Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression
- (2008) Shauna A. Lee et al. DNA REPAIR
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now